What is PCSK9 — and is this the next big thing in cholesterol management?

PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that degrades LDL receptors on the liver surface, reducing the liver's capacity to clear LDL particles, PCSK9 inhibitors (evolocumab/Repatha, alirocumab/Praluent) are injectable antibodies that block PCSK9, increasing LDL receptor recycling and dramatically reducing ApoB and LDL-C (by 50–60% beyond statin therapy), with the FOURIER and ODYSSEY trials showing significant cardiovascular event reduction in high-risk patients who are statin-intolerant or require more aggressive lipid lowering (Sabatine et al., NEJM, 2017).

PCSK9 inhibitors are currently used for men with: confirmed statin intolerance (unable to tolerate any statin due to muscle symptoms), familial hypercholesterolemia (genetic condition producing very high LDL-C from birth), or very high-risk patients requiring ApoB below 65 mg/dL that statins alone cannot achieve. Cost ($500–$600/month before insurance) has been the primary barrier to wider use, though this is declining with biosimilar approvals. Small-molecule PCSK9 inhibitors (inclisiran, oral formulations in development) are expanding the accessibility of this approach.

Honesty Scale: Solid (1) for PCSK9 inhibitors reducing ApoB and cardiovascular events in high-risk patients.

What to do: If you have familial hypercholesterolemia, statin intolerance with uncontrolled LDL/ApoB, or are post-cardiovascular event with ApoB still above 65 mg/dL on maximal statin, discuss PCSK9 inhibitor access with your cardiologist. Insurance authorization typically requires documented statin intolerance or failure.

For the full picture, read The ApoB/Lp(a)/Lipids Deep Dive